Talibegron HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328078

CAS#: 178600-17-4 (HCl)

Description: Talibegron, also known as D-2079; ICI-D-2079; SCH-417849; ZD-2079, is an β3 adrenergic receptor agonist potentially for the treatment of obesity and type 2 diabetes.

Chemical Structure

img
Talibegron HCl
CAS# 178600-17-4 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 328078
Name: Talibegron HCl
CAS#: 178600-17-4 (HCl)
Chemical Formula: C18H22ClNO4
Exact Mass: 0.00
Molecular Weight: 351.827
Elemental Analysis: C, 61.45; H, 6.30; Cl, 10.08; N, 3.98; O, 18.19

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 178600-17-4 (HCl)   146376-58-1 (free base)  

Synonym: Talibegron HCl, Talibegron hydrochloride, D-2079, ICI-D-2079, SCH-417849, ZD-2079, D2079, ICI-D2079, SCH417849, ZD2079

IUPAC/Chemical Name: (R)-2-(4-(2-((2-hydroxy-2-phenylethyl)amino)ethoxy)phenyl)acetic acid hydrochloride

InChi Key: KCEFVYIWOQSJCH-LMOVPXPDSA-N

InChi Code: InChI=1S/C18H21NO4.ClH/c20-17(15-4-2-1-3-5-15)13-19-10-11-23-16-8-6-14(7-9-16)12-18(21)22;/h1-9,17,19-20H,10-13H2,(H,21,22);1H/t17-;/m0./s1

SMILES Code: O=C(O)CC1=CC=C(OCCNC[C@H](O)C2=CC=CC=C2)C=C1.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 351.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kozłowska H, Schlicker E, Kozłowski M, Siedlecka U, Laudański J, Malinowska B. Ligands at beta2-, beta3-, and the low-affinity state of beta1-adrenoceptors block the alpha1-adrenoceptor-mediated constriction in human pulmonary and rat mesenteric arteries. J Cardiovasc Pharmacol. 2005 Jul;46(1):76-82. PubMed PMID: 15965358.

2: Zelaszczyk D, Zakrzeska A, Kwolek G, Malinowska B, Schlicker E. A search for presynaptic beta3-adrenoceptors in the rat. Fundam Clin Pharmacol. 2005 Apr;19(2):147-53. PubMed PMID: 15810894.

3: Kozłowska H, Szymska U, Schlicker E, Malinowska B. Atypical beta-adrenoceptors, different from beta 3-adrenoceptors and probably from the low-affinity state of beta 1-adrenoceptors, relax the rat isolated mesenteric artery. Br J Pharmacol. 2003 Sep;140(1):3-12. PubMed PMID: 12967929; PubMed Central PMCID: PMC1574016.

4: Mallem MY, Gogny M, Gautier F, Bucas V, Desfontis JC. Evaluation of beta3-adrenoceptor-mediated relaxation in intact and endotoxin-treated equine digital veins. Am J Vet Res. 2003 Jun;64(6):708-14. PubMed PMID: 12828256.

5: Buemann B, Toubro S, Astrup A. Effects of the two beta3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects. Int J Obes Relat Metab Disord. 2000 Dec;24(12):1553-60. PubMed PMID: 11126205.

6: Brawley L, Shaw AM, MacDonald A. Role of endothelium/nitric oxide in atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Eur J Pharmacol. 2000 Jun 16;398(2):285-96. PubMed PMID: 10854841.

7: Brawley L, Shaw AM, MacDonald A. Beta 1-, beta 2- and atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Br J Pharmacol. 2000 Feb;129(4):637-44. PubMed PMID: 10683187; PubMed Central PMCID: PMC1571885.

8: MacDonald A, McLean M, MacAulay L, Shaw AM. Effects of propranolol and L-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. J Auton Pharmacol. 1999 Jun;19(3):145-9. PubMed PMID: 10511470.

9: Waghe M, Westwood R, Nunn G, Kalinowski A, Aldridge A. Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70. PubMed PMID: 10207980.

10: Sarsero D, Molenaar P, Kaumann AJ. Validity of (-)-[3H]-CGP 12177A as a radioligand for the 'putative beta4-adrenoceptor' in rat atrium. Br J Pharmacol. 1998 Feb;123(3):371-80. PubMed PMID: 9504376; PubMed Central PMCID: PMC1565174.

11: Trayhurn P, Duncan JS, Rayner DV, Hardie LJ. Rapid inhibition of ob gene expression and circulating leptin levels in lean mice by the beta 3-adrenoceptor agonists BRL 35135A and ZD2079. Biochem Biophys Res Commun. 1996 Nov 12;228(2):605-10. PubMed PMID: 8920957.

12: Kaumann AJ, Molenaar P. Differences between the third cardiac beta-adrenoceptor and the colonic beta 3-adrenoceptor in the rat. Br J Pharmacol. 1996 Aug;118(8):2085-98. PubMed PMID: 8864547; PubMed Central PMCID: PMC1909870.

13: Hoffstedt J, Lönnqvist F, Shimizu M, Blaak E, Arner P. Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34. PubMed PMID: 8696421.

14: Malinowska B, Schlicker E. Mediation of the positive chronotropic effect of CGP 12177 and cyanopindolol in the pithed rat by atypical beta-adrenoceptors, different from beta 3-adrenoceptors. Br J Pharmacol. 1996 Mar;117(5):943-9. PubMed PMID: 8851515; PubMed Central PMCID: PMC1909427.

15: Pietri-Rouxel F, Strosberg AD. Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundam Clin Pharmacol. 1995;9(3):211-8. Review. PubMed PMID: 7557816.